1. Home
  2. NAT vs GERN Comparison

NAT vs GERN Comparison

Compare NAT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordic American Tankers Limited

NAT

Nordic American Tankers Limited

HOLD

Current Price

$3.38

Market Cap

669.1M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.33

Market Cap

753.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAT
GERN
Founded
1995
1990
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
669.1M
753.3M
IPO Year
1997
1996

Fundamental Metrics

Financial Performance
Metric
NAT
GERN
Price
$3.38
$1.33
Analyst Decision
Hold
Buy
Analyst Count
2
7
Target Price
$3.25
$3.00
AVG Volume (30 Days)
2.9M
7.1M
Earning Date
11-28-2025
11-05-2025
Dividend Yield
10.09%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$294,820,000.00
$183,403,000.00
Revenue This Year
N/A
$147.34
Revenue Next Year
$32.00
$39.11
P/E Ratio
$374.40
N/A
Revenue Growth
N/A
522.13
52 Week Low
$2.13
$1.04
52 Week High
$3.93
$3.80

Technical Indicators

Market Signals
Indicator
NAT
GERN
Relative Strength Index (RSI) 35.47 55.61
Support Level $3.34 $1.30
Resistance Level $3.78 $1.45
Average True Range (ATR) 0.10 0.08
MACD -0.03 0.01
Stochastic Oscillator 7.96 53.70

Price Performance

Historical Comparison
NAT
GERN

About NAT Nordic American Tankers Limited

Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: